DDInter1557 DDInter1435
An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Quinine {u} (Compound) resembles {v} (Compound) Quinidine barbiturate
Quinine {u} (Compound) treats {v} (Disease) malaria
Quinine {u} (Compound) binds {v} (Gene) SLC22A4
Quinine {u} (Compound) upregulates {v} (Gene) CPVL
Quinine {u} (Compound) downregulates {v} (Gene) DNAJA3
Quinine {u} (Compound) causes {v} (Side Effect) Optic neuritis
Quinine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Quinine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doxycycline
Quinine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostemsavir
Quinine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aminoglutethimide
Quinine (Compound) resembles Quinidine barbiturate (Compound)
Quinine (Compound) treats malaria (Disease)
Quinine (Compound) binds SLC22A4 (Gene)
Quinine (Compound) upregulates CPVL (Gene)
Quinine (Compound) downregulates DNAJA3 (Gene)
Quinine (Compound) causes Optic neuritis (Side Effect)
Quinine may cause a minor interaction that can limit clinical effects when taken with Modafinil
Quinine may cause a minor interaction that can limit clinical effects when taken with Doxycycline
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide